SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Tenaya Therapeutics, Inc. (TNYA) has a negative trailing P/E of -1.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 1.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -79.49%, forward earnings yield 59.17%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.01); analyst target implies upside (+206.7%).
- Forward P/E 1.7 — analysts expect a return to profitability with estimated EPS of $0.45 for FY2028.
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -79.49% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 59.17% as earnings recover.
- Analyst consensus target $2.33 (+206.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 64/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TNYA
Valuation Multiples
P/E (TTM)-1.3
Forward P/E1.7
PEG Ratio0.01
Forward PEG0.01
P/B Ratio0.92
P/S Ratio0.00
EV/EBITDA-0.4
Per Share Data
EPS (TTM)$-0.59
Forward EPS (Est.)$0.45
Book Value / Share$0.81
Revenue / Share$0.00
FCF / Share$-0.45
Yields & Fair Value
Earnings Yield-79.49%
Forward Earnings Yield59.17%
Dividend Yield0.00%
Analyst Target$2.33 (+206.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-16.2 |
0.00 |
-9.55 |
0.00 |
- |
| 2020 |
-16.4 |
7.81 |
4.53 |
0.00 |
- |
| 2021 |
-10.8 |
-0.13 |
2.81 |
0.00 |
- |
| 2022 |
-0.7 |
-0.01 |
0.37 |
0.00 |
- |
| 2023 |
-1.9 |
0.05 |
1.71 |
0.00 |
- |
| 2024 |
-1.1 |
0.05 |
1.31 |
0.00 |
- |
| 2025 |
-1.2 |
0.02 |
0.88 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.63 |
$0.00 |
$-25.78M |
- |
| 2020 |
$-0.93 |
$0.00 |
$-38.31M |
- |
| 2021 |
$-1.69 |
$0.00 |
$-69.65M |
- |
| 2022 |
$-2.76 |
$0.00 |
$-123.66M |
- |
| 2023 |
$-1.68 |
$0.00 |
$-124.08M |
- |
| 2024 |
$-1.31 |
$0.00 |
$-111.13M |
- |
| 2025 |
$-0.59 |
$0.00 |
$-90.6M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.43 |
$-0.57 – $-0.26 |
$8.33M |
$8.33M – $8.33M |
7 |
| 2027 |
$-0.45 |
$-5.33 – $14.74 |
$103.74M |
$103.74M – $103.74M |
4 |
| 2028 |
$0.45 |
$-0.44 – $2.03 |
$277.89M |
$277.89M – $277.89M |
3 |
| 2029 |
$3.33 |
$3.33 – $3.33 |
$1.36B |
$1.36B – $1.36B |
1 |
| 2030 |
$5.84 |
$5.84 – $5.84 |
$2.41B |
$2.41B – $2.41B |
1 |
